The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.

The invention provides methods for synthesizing the compound (2R,3S,4E)-N-methyl-5-(4-pentylphenyl)-2-aminopent-4-ene-1,3-diol, also known as SK1-I, and intermediate compounds used in its synthesis.

The invention provides methods for synthesizing the compound (2R,3S,4E)-N-methyl-5-(4-pentylphenyl)-2-aminopent-4-ene-1,3-diol, also known as SK1-I, and intermediate compounds used in its synthesis.

The invention provides methods for synthesizing the compound (2R,3S,4E)-N-methyl-5-(4-pentylphenyl)-2-aminopent-4-ene-1,3-diol, also known as SK1-I, and intermediate compounds used in its synthesis.

The invention provides methods for synthesizing the compound (2R,3S,4E)-N-methyl-5-(4-pentylphenyl)-2-aminopent-4-ene-1,3-diol, also known as SK1-I, and intermediate compounds used in its synthesis.

Provided are inhibitors of sphingosine kinase Type I and their use in the treatment of asthma, among other indications and diseases.

Provided are inhibitors of sphingosine kinase Type I and their use in the treatment of asthma, among other indications and diseases.

The present invention relates to a compound of formula XXII and a compound of formula 17ya, which are defined as anywhere in the specification, to a composition comprising the same, and to a method of using thereof in the treatment of various forms of cancer.

The present invention relates to a compound of formula XXII and a compound of formula 17ya, which are defined as anywhere in the specification, to a composition comprising the same, and to a method of using thereof in the treatment of various forms of cancer.

Provided herein is a process for producing a polyamide (P) by reaction of a mixture (M) including at least one lactam (component (A)), at least one catalyst (component (B)), at least one activator (component (C)), and at least one oxazolidine derivative (component (D)). Further provided herein is the mixture (M) and the use of an oxazolidine derivative for increasing the crystallization rate of a polyamide (P). Also provided herein is the use of an oxazolidine derivative in a polyamide (P) for producing a molded article from the polyamide (P) for reducing the demolding time of the molded article and the use of an oxazolidine derivative for removing water from a reaction mixture (RM).